Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:41:09 2025-07-08 am EDT			5-day change	1st Jan Change
27.18 ^EUR	+3.94%		+6.44%	+40.73%

Jul. 08	German Equities Jump Amid EU-US Trade Deal Optimism	MT
Jul. 08	MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms caused by menopause	RE

BAYER AG : Goldman Sachs raises its recommendation to Buy

Published on 06/05/2025 at 02:41

Goldman Sachs's analyst James Quigley has upgraded his rating from Neutral to Buy. The target price has been raised to EUR 33 from EUR 29.10.

Latest news about Bayer AG

German Equities Jump Amid EU-US Trade Deal Optimism	Jul. 08	MT
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms caused by menopause	Jul. 08	RE
UK Clears Bayer Medicine for Menopause-related Hot Flashes	Jul. 08	MT
Bayer Treats First Patient in Early-stage Trial for Retinal Disorder Drug Candidate	Jul. 08	MT
Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases	Jul. 08	CI
Bayer: testing OpCT-001, an experimental cell therapy	Jul. 08	CF
Vincerx Pharma, Inc. and Vnrx, Inc Announces Termination of License Agreement with Bayer Aktiengesellschaft and Bayer Intellectual Property Gmbh	Jul. 07	CI
BAYER AG : JP Morgan gives a Neutral rating	Jul. 07	ZD
BAYER AG : Goldman Sachs keeps its Buy rating	Jul. 04	ZD
General Mills changing Nature Valley labels after lawsuit's herbicide claim	Jul. 01	RE
Bayer Announces Executive Changes for North America	Jul. 01	CI
BAYER AG : UBS reaffirms its Neutral rating	Jul. 01	ZD
BAYER AG : JP Morgan reiterates its Neutral rating	Jun. 30	ZD
European shares see monthly declines as markets eye trade developments	Jun. 30	RE
BAYER AG : Jefferies remains Neutral	Jun. 30	ZD
Supreme Court Seeks US Government Advice on Bayer's Glyphosate Appeal	Jun. 30	RE
Bayer Sees Request for US Solicitor General's Opinion in Weedkiller Case as 'Encouraging Step'	Jun. 30	MT
US Supreme Court seeks Justice Department views on Bayer's Roundup appeal	Jun. 30	RE
US Supreme Court seeks Justice Department views on Bayer's Roundup appeal	Jun. 30	RE
Bayer says U.S. Supreme Court asks solicitor general for opinion in glyphosate case	Jun. 30	RE
Bayer says U.S. Supreme Court asks solicitor general for opinion in glyphosate case	Jun. 30	RE
German Stocks Rise on EU-US Trade Deal Hopes	Jun. 27	MT
Berenberg leaves Bayer at 'Hold' – target €26	Jun. 27	DP
BAYER AG : Gets a Neutral rating from Berenberg	Jun. 27	ZD
Bayer: EU approves treatment for AMD and DMO	Jun. 27	CF

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

90,885

Sector

Pharmaceuticals

Calendar

Aug. 06 - Q2 2025 Earnings Release

More about the company